PCSK9 and coronary artery disorder: Previous work in the SWEDEHEART registry on LDL-C changes after MI have shown that even after optimizing statin therapy, about 80% of patients do not reach LDL-C goals, and modelling shows that about another 20%–25% reach goals if ezetimibe is added, with the majority of the remainder predicted to achieve targets after the addition of PCSK9 monoclonal antibody.22 This is in keeping with similar simulation studies conducted in stable patients with coronary artery disease.23